Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments. First Quarter 2025 Highlights: "Our focus remains firmly on advancing (Z)-endoxifen as a ...